News Column

Date change for Annual General Meeting

February 14, 2014

The Board of Directors of Genovis AB (publ) has decided to postpone the Annual General Meeting. The AGM, which was to be held on April 24, will be postponed. The new date for the AGM is May 20, 2014. For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 ABOUT GENOVIS

Genovisí business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00

This information was brought to you by Cision,c9537404

The following files are available for download:

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Cision

Story Tools